Suppr超能文献

倍他米松与地塞米松预防极低出生体重儿发病情况的比较

Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates.

作者信息

Feldman Deborah M, Carbone Jeannine, Belden Laura, Borgida Adam F, Herson Victor

机构信息

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Hartford Hospital, Hartford, CT, USA.

出版信息

Am J Obstet Gynecol. 2007 Sep;197(3):284.e1-4. doi: 10.1016/j.ajog.2007.07.010.

Abstract

OBJECTIVE

The purpose of this study was to compare neonatal outcomes in very-low-birthweight infants who were exposed to antenatal betamethasone vs dexamethasone.

STUDY DESIGN

We reviewed all inborn very-low-birthweight infants from January 1997 through February 2006. Maternal medical records were reviewed to determine the type of antenatal steroids that each patient received; neonatal outcomes were compared using chi-square and Student t tests.

RESULTS

There were 334 very-low-birthweight infants who met the criteria for evaluation: 186 infants received betamethasone, and 148 infants received dexamethasone. There were no differences in race, gestational age at delivery, or mean birthweight between the 2 groups. There were significantly lower rates of respiratory distress syndrome and bronchopulmonary dysplasia in the betamethasone group, compared with the dexamethasone group. Other neonatal outcomes were similar in both groups.

CONCLUSION

Antenatal betamethasone was associated with a significantly lower rate of pulmonary complications caused by prematurity, when compared with dexamethasone.

摘要

目的

本研究旨在比较接受产前倍他米松与地塞米松治疗的极低出生体重儿的新生儿结局。

研究设计

我们回顾了1997年1月至2006年2月期间所有出生的极低出生体重儿。查阅产妇病历以确定每位患者接受的产前类固醇类型;使用卡方检验和学生t检验比较新生儿结局。

结果

有334名极低出生体重儿符合评估标准:186名婴儿接受了倍他米松治疗,148名婴儿接受了地塞米松治疗。两组在种族、分娩时的孕周或平均出生体重方面无差异。与地塞米松组相比,倍他米松组的呼吸窘迫综合征和支气管肺发育不良发生率显著较低。两组的其他新生儿结局相似。

结论

与地塞米松相比,产前倍他米松与因早产引起的肺部并发症发生率显著降低相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验